Current studies have found that IL-17 could promote tumor growth through IL-6-Stat3 signaling pathway (Li et al., 2020b), and also release IFN-γ and other cytokines through stimulating T cells, dendritic cells, NK cells and other immune cells, thus inhibiting tumor growth (Kryczek et al., 2009; Martin-Orozco et al., 2009). Here, STAT3 is linked to neoplasm.